Open Heart (Feb 2021)

Patient delay and benefit of timely reperfusion in ST-segment elevation myocardial infarction

  • Tim Friede,
  • Thomas Meyer,
  • Karl Heinrich Scholz,
  • Björn Lengenfelder,
  • Christian Vahlhaus,
  • Jörn Tongers,
  • Steffen Schnupp,
  • Rainer Burckhard,
  • Nicolas von Beckerath,
  • Hans-Martin Grusnick,
  • Andreas Jeron,
  • Klaus Dieter Winter,
  • Sebastian K G Maier,
  • Michael Danner,
  • Jürgen vom Dahl,
  • Stefan Neef,
  • Stefan Stefanow

DOI
https://doi.org/10.1136/openhrt-2021-001650
Journal volume & issue
Vol. 8, no. 1

Abstract

Read online

Background In patients with ST-segment elevation myocardial infarction (STEMI), it is unknown how patient delay modulates the beneficial effects of timely reperfusion.Aims To assess the prognostic significance of a contact-to-balloon time of less than 90 min on in-hospital mortality in different categories of symptom-onset-to-first-medical-contact (S2C) times.Methods A total of 20 005 consecutive patients from the Feedback Intervention and Treatment Times in ST-segment Elevation Myocardial Infarction (FITT-STEMI) programme treated with primary percutaneous coronary intervention (PCI) were included.Results There were 1554 deaths (7.8%) with a J-shaped relationship between mortality and S2C time. Mortality was 10.0% in patients presenting within 1 hour, and 4.9%, 6.0% and 7.3% in patient groups with longer S2C intervals of 1–2 hours, 2–6 hours and 6–24 hours, respectively. Patients with a short S2C interval of less than 1 hour (S2C<60 min) had the highest survival benefit from timely reperfusion with PCI within 90 min (OR 0.27, 95% CI 0.23 to 0.31, p<0.0001) as compared with the three groups with longer S2C intervals of 1 hour<S2C≤2 hours (OR 0.44, 95% CI 0.33 to 0.59, p<0.0001), 2 hours<S2C≤6 hours (OR 0.49, 95% CI 0.38 to 0.64, p<0.0001) and 6 hours<S2C≤24 hours (OR 0.42, 95% CI 0.30 to 0.58, p<0.0001).Conclusions Timely reperfusion with a contact-to-balloon time of less than 90 min is most effective in patients presenting with short S2C intervals of less than 1 hour, but has also beneficial effects in patients with S2C intervals of up to 24 hours.Trial registration number NCT00794001.